Comparative Pharmacology
Head-to-head clinical analysis: MAOLATE versus PARAFON FORTE DSC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAOLATE versus PARAFON FORTE DSC.
MAOLATE vs PARAFON FORTE DSC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MAOLATE is a centrally acting muscle relaxant that does not directly relax skeletal muscle. Its mechanism of action is not fully understood, but it is thought to act via inhibition of polysynaptic reflexes at the spinal level and possibly through sedation.
Chlorzoxazone acts on the central nervous system (CNS) at the spinal cord level, possibly by depressing polysynaptic reflexes, producing skeletal muscle relaxation without affecting neuromuscular transmission.
250 mg orally 4 times daily or 500 mg orally 3 times daily for 21 days; maximum daily dose 2000 mg.
Adults: 4 g (500 mg x 8 tablets) orally every 6-8 hours as needed; maximum 8 g (16 tablets) per 24 hours.
None Documented
None Documented
Terminal elimination half-life: 8-12 hours (prolonged in renal impairment, up to 20-30 hours in severe renal failure; dose adjustment required for CrCl <30 mL/min)
1-3 hours (terminal); clinically relevant for dosing intervals of 4-6 hours.
Renal: ~70% as unchanged drug and metabolites; Biliary/Fecal: ~30%
Primarily renal (85-95% as glucuronide conjugates and unchanged drug; <5% fecal).
Category C
Category C
Muscle Relaxant
Muscle Relaxant/Analgesic Combination